For most food, botanical and supplement manufacturers, DNA authentication has meant the same thing for twenty years: pack a sample, send it to a laboratory, wait, and receive a report. The microarray changes that arrangement, because the test can run where the product is made. That is a bigger shift than it first sounds.
The send-away model, and what it costs
Outsourcing a DNA test is not wrong. It buys expertise you may not have, and for an occasional dispute it is the sensible answer. But the model shapes how a QA team can use DNA, usually in three ways.
- You test rarely, because each test is an event. Packing, shipping and waiting mean DNA testing tends to be reserved for new suppliers, complaints and audits, rather than routine verification.
- The answer arrives after the decision. If the lot has already shipped by the time the report lands, the result documents a problem instead of preventing one.
- You get the conclusion, not the method. When a customer or auditor asks how a species was identified, the answer usually has to be requested from someone else.
None of this is a complaint about laboratories. It is a description of what happens when the test sits outside the process it is meant to control.
What moves when the microarray moves
A QAID microarray product is a slide plus an analysis workflow. Your team extracts DNA from the sample, runs it on the slide, scans the slide on a compatible microarray scanner and uploads the data to the QAID App, which checks the assay controls and reports what was identified. The sample never leaves the building.
The practical consequences show up quickly.
Testing becomes routine rather than exceptional. When a run is something your team does on a Tuesday, incoming-goods verification and periodic supplier checks become realistic. The value of DNA authentication comes from frequency as much as from accuracy: one test on one lot tells you about that lot, while a routine program tells you about a supplier.
The timing works with the decision, not after it. Running in-house means a screening result can sit alongside your other release checks, so a question about identity is raised while the lot is still under your control.
The evidence stays with you. Results, assay controls and supporting signal data live in your own QAID App account. When somebody asks how a result was reached, your team can answer from its own records rather than requesting a file from a third party.
Your people build the judgement. The technician who runs the slide and the QA manager who reads the result start to recognise what a normal run looks like for their materials. That familiarity is the part no report can deliver, and it is what makes an unusual result useful instead of alarming.
What you take on
Bringing a method in-house means owning it, and it is fair to be honest about that.
- A capable bench. DNA extraction and handling need a properly set up area and sensible separation of work. Laboratories already running molecular methods usually have it.
- A compatible scanner. The slide is read on a microarray scanner in your laboratory. Compatibility and export settings are confirmed before you order anything.
- Trained people. Not a one-off induction: people who have run your own materials, on your own equipment, and seen what a failed control looks like.
- Procedures of your own. When a result flags an undeclared species, your QA system, not the supplier of the test, decides what happens next.
The workload does not disappear; it changes shape. Instead of managing shipments and chasing reports, you are managing a method. Most QA teams find that trade worth making, because the second is something they can improve.
Where the supplier still matters
Running the test yourself does not mean being on your own. QAID designs the microarray products, curates the reference panels behind every call, builds the QAID App that reads the data, and trains the team that runs it. What changes is the division of labour: QAID supplies the system and the expertise, and your laboratory produces and owns the result.
That division matters for a reason that goes beyond convenience. The QA decision, release, hold, retest or escalate, was always yours. Under the send-away model the evidence behind that decision belonged to someone else. In-house, the evidence and the decision sit in the same place.
Is it for every lab?
No. If you test a handful of samples a year, or your question is a one-off legal dispute, sending it out is still reasonable. The case for in-house strengthens when identity is a recurring risk: many suppliers, materials that are easy to substitute, formulations with several botanical or animal ingredients, or a customer base that asks how you know.
It is also not an all-or-nothing choice. Plenty of laboratories start by screening in-house and sending the small number of results that matter commercially for confirmatory testing elsewhere. Screening broadly and confirming narrowly is usually cheaper and faster than confirming everything, and it is exactly what a multi-target panel is good at.
Starting the conversation
The first question is not which product to buy. It is which QA question you need answered often enough that owning the method pays. If you can name that question, the rest, the product, the setup, the training, follows from it.
Read how QAID works for the mechanics, getting started for what implementation involves, or talk to a QAID scientist about your own materials.